Cell & Gene Therapies
TIA brings together five key national cell and gene therapy development and manufacturing facilities (shown in the map below) to facilitate the translation from discovery to clinical benefit. Our consortium of CGT facilities has far reaching expertise to support and assist your development across the spectrum of cell and gene therapies regardless of your stage of development.
The highly personalised nature of many of the cell and gene therapies requires unique quality control tests for each therapy. The facilities can offer in process and for release quality control testing. They will be able to identify QC tests required and assist in work up of specific tests for your product.
CROSSING THE VALLEY OF DEATH : Guidance for Researchers Translating a Research Discovery into an Advanced Therapeutic Product
TIA has produced a guidance document to assist you in translating your research discovery into an advanced therapeutic product.
It is never too early to reach out to the facilities within TIA’s Cell & Gene Therapy Capability for advice on making the transition from research to development.
Early engagement with TIA or one of the facilities will enable you to leverage their significant expertise and expedite your translation to clinical development.
Understanding GMP requirements early will save you time and money.